Primary care clinicians are often the most accessible to patients and play a crucial role in the early detection and ...

Crizanlizumab (Adakveo) failed to outperform placebo in patients with sickle cell disease, the phase III STAND trial showed.

Adding tilsotolimod to ipilimumab did not improve response or survival outcomes in patients with advanced melanoma.

ImmunityBio, Inc. , a leading immunotherapy company, today announced U.S. Urology Partners, one of the nation's largest independent providers of urology and related specialty services, is one of the ...